Overview

Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in participants with open-angle glaucoma or ocular hypertension.

Phase:

Phase 4

Details

Lead Sponsor:

Alcon Research

Treatments:

Brimonidine Tartrate
Brimonidine Tartrate, Timolol Maleate Drug Combination
Brinzolamide
Maleic acid
Timolol